Immunocore (NASDAQ:IMCR) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Immunocore (NASDAQ:IMCR) announced its quarterly earnings data on Wednesday. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16), Zacks reports. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%.

Immunocore Stock Performance

Shares of IMCR traded up $1.28 during trading hours on Wednesday, hitting $30.49. The company’s stock had a trading volume of 76,482 shares, compared to its average volume of 217,221. Immunocore has a 52-week low of $27.69 and a 52-week high of $72.56. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -31.72 and a beta of 0.77. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The business has a 50 day simple moving average of $29.98 and a two-hundred day simple moving average of $31.97.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Needham & Company LLC reissued a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.